AbbVie to acquire Apogee in $10.9 billion immunology power play
Under the agreement, Apogee shareholders will receive $135.11 per share in cash, and the transaction has been unanimously approved by both companies’ boards
Under the agreement, Apogee shareholders will receive $135.11 per share in cash, and the transaction has been unanimously approved by both companies’ boards
Subscribe To Our Newsletter & Stay Updated